Effects of acute or 3-day treatments of Hypericum caprifoliatum Cham. & Schltdt. (Guttiferae) extract or of two established antidepressants on basal and stress-induced increase in serum and brain corticosterone levels
Restricted accessOtherFirst published online August, 2008
Effects of acute or 3-day treatments of Hypericum caprifoliatum Cham. & Schltdt. (Guttiferae) extract or of two established antidepressants on basal and stress-induced increase in serum and brain corticosterone levels
Since depressive patients present alterations in the hypothalamo-pituitary-adrenal (HPA) axis that are normalised by antidepressants, this HPA axis has been considered as a target of their actions. We have investigated the mechanism of action of a cyclohexane extract of Hypericum caprifoliatum (HCP), which displays antidepressant like activity, by studying, in mice, the influence of HCP and of two established antidepressant drugs, imipramine and bupropion, administered either acutely or semi-chronically (once a day, three consecutive days), on serum and brain cortex corticosterone levels, either in basal conditions or shortly after a forced-swimming session (FSS). Administered acutely, imipramine (20 mg/kg, per os (p.o.)), bupropion (30 mg/kg, p.o.) and HCP (360 mg/kg, p.o.) significantly reduced the immobility time and had no effects on FSS-induced increase of serum and cortical corticosterone levels. Conversely, 3 days repeated treatment with imipramine or bupropion resulted in a significant reduction of immobility time and FSS-induced increase of serum and cortical corticosterone levels. In a different way, repeated treatment with HCP significantly reduced the immobility time and only cortical corticosterone levels in stressed mice. These results indicate that short-term treatments with antidepressants are sufficient to induce modifications in the HPA axis reactivity to stress; and that apparently HCP has an influence on corticosterone levels by a mechanism diverse from the other tested antidepressants.
Ascher J.A., Cole J.O., Colin J-N., Feighner J.P., Ferris R.M., Fibiger H.C., Golden R.N., Martin P., Potter W.Z., Richelson E., Sulser F. (1995) Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry56: 395-401
2.
Attenburrow M.J., Mitter P.R., Whale R., Terao T., Cowen P.J. (2001) Low-dose citalopram as a 5-HT neuroendocrine probe . Psychopharmacology155: 323-326
3.
Auriacombe M., Reneric J.P., Moal M.L. (1997) Animal models of anhedonia. Psychopharmacology134: 337-338
4.
Barden N., Reul J M., Holsboer F. (1995) Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system?Trends Neurosci18: 6-11
5.
Barnes J., Anderson L., Phillipson J.D. (2001) St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol53: 583-600
6.
Beerhues L. (2006) Molecules of interest. Hyperforin Phytochem67: 2201-2207
7.
Bourgeois S., Gruol D.J., Newby R.F., Rajah F.M. (1993) Expression of an mdr gene is associated with new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol7: 840-851
8.
Brenner R., Azbel V., Madhusoodanan S., Pawlowska M. (2000) Comparison of an extract of Hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther22: 411-419
9.
Burke M.J., Preskorn S.H. (1999) Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice. Clin Pharmacokinet37: 147-165
10.
Butterweck V., Wall A., Liefländer-Wulf U., Winterhoff H., Nahrstedt A. (1997) Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry30 (Suppl 2): 117-124
11.
Butterweck V., Petereit F., Winterhoff H., Nahrstedt A. (1998) Solubilized hypericin and pseudo-hypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med64: 291-294
12.
Butterweck V., Jürgenliemk G., Nahrstedt A., Winterhoff H. (2000) Flavonoids from Hypericum perforatum show antidepressant activity in forced swimming test. Planta Med66: 3-6
13.
Butterweck V., Winterhoff H., Herkenham M. (2001) St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol Psychiatr6: 547-564
14.
Butterweck V., Hegger M., Winterhoff H. (2004) Flavonoids of St. John's Wort reduce HPA axis function in the rat. Planta Med70: 1008-1011
15.
Bystrov N.S., Chernov B., Dobrynin V.N., Kolosov M.N. (1975) The structure of hyperforin. Tetrahedron Lett16: 2791-2794
16.
Chatterjee S.S., Nöldner M., Koch E., Erdelmeier C. (1998a) Antidepressant activity of Hypericum perforatum and hyperforin, the neglected possibility. Pharmacopsychiatry31: 7-15
17.
Chatterjee S.S., Bhattacharya S.K., Wonnemann M., Singer A., Müller W.E. (1998b) Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sci63: 499-510
18.
Chrousos G.P., Gold P.W. (1998) A healthy body in a healthy mind- and vice versa the damaging power of uncontrollable stress. J Clin Endocrinol Metabol83: 1842-1845
19.
Cotter D., Pariante C.M. (2002) Stress and the progression of the developmental hypothesis of schizophrenia. Br J Psychiat181: 363-365
20.
Dall'Agnol R., Ferraz A., Bernardi A.P., Albring D., Nör C., Sarmento L., Lamb L., Hass M., von Poser G., Schapoval E E S (2003) Antimicrobial activity of some Hypericum species . Phytomedicine10: 511-516
21.
Daudt R., von Poser G.L., Neves G., Rates S M K (2000) Screening for the antidepressant activity of some species of Hypericum from South Brazil. Phytother Res15: 344-346
22.
de Kloet E.R., Vreugdenhil E., Oitzl M.S., Joels M. (1998) Brain corticosteroid receptor balance in health and disease. Endocr Rev19: 269-301
23.
Delbende C., Contesse V., Mocaer E., Kamoun A., Vaudry H. (1991) The novel antidepressant, tianeptine, reduces stress-evoked stimulation of the hypothalamo-pituitary-adrenal axis. Eur J Pharmacol202: 391-396
24.
Duncan G.E., Knapp D.J., Carson S.W., Breese G.R. (1998) Differential effects of chronic antidepressant treatment onswim stress- and fluoxetineinduced secretion of corticosterone and progesterone. J Pharmacol Exp Ther285: 579-587
25.
Durr D., Stieger B., Kullak-Ublick G.A., Rentsch K.M., Steinert H.C., Meier P.J., Fattinger K. (2000) St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther68: 598-604
26.
Feighner J.P., Gardner E.A., Johnston A., Batey S.R., Khayrallah M.A., Ascher J.A., Lineberry C.G. (1991) Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiat52: 329-335
27.
Ferraz A., Bordignon S., Mans D., Schmitt A., Ravazzolo A.P. (2002) Screening for the presence of hypericins in southern Brazilian species of Hypericum (Guttiferae). Pharm Biol40: 294-297
28.
Ferris R.M., Cooper B.R. (1993) Mechanism of antidepressant activity of bupropion . J Clin Psychiat11: 2-14
29.
Foa E.B., Zinbarg R., Rothbaum B.O. (1992) Uncontrollability and unpredictability in post-traumatic stress disorder: an animal model. Psychol Bull112: 218-238
30.
Franklin M., Chi J.D, Mannel M., Cowen P.J. (2000) Acute effects of LI 160 (extract of Hypericum perforatum, St John's wort) and two of its constituents on neuroendocrine responses in the rat. J Psychopharmacol14: 360-363
31.
Franklin M., Reed A., Murck H. (2004) Sub-chronic treatment with an extract of Hypericum perforatum (St John's wort) significantly reduces cortisol and corticosterone in the rat brain. Eur Neuropsychopharmacol14: 7-10
32.
Frazer A. (2000) Norepinephrine involvement in antidepressant action . J Clin Psychiat61 (Suppl 10): 25-30
Glowinski J., Iversen L.L. (1966) Regional studies of catecholamines in the rat brain III. Subcellular distribution of endogenous and exogenous catecholamines in various brain regions. Biochem Pharmacol15: 977-987
35.
Gold P.W., Licinio J., Wong M.L., Chrousos G.P. (1995) Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N Y Acad Sci771: 716-729
36.
Grosel J.E., Fleschner M., Watkins L.R., Maier S.F. (1993) Opioid and non opioid interactions in two forms of stress-induced analgesia. Pharmacol Biochem Behav45: 161-172
37.
Henn F.A., Edwards E., Muneyyirci J. (1993) Animal model of depression. Clin Neurosci1: 152-156
38.
Hennessy M., Kelleher D., Spiers J.P., Barry M., Kavanagh P., Back D., Mulcahy F., Feely J. (2002) St John's wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol53: 75-82
39.
Hennig J., Lange N., Haag A., Rohrmann S., Netter P. (2000) Reboxetine in a neuroendocrine challenge paradigm: evidence for high cortisol responses in healthy volunteers scoring high on subclinical depression. Int J Neuropsychopharmacol3: 193-201
40.
Hirschfeld R M A (2000) History and evolution of the monoamine hypothesis of depression. J Clin Psychiat61: 4-6
41.
Holsboer F. (2000) The corticosteroid receptor hypothesis of depression . Neuropsychopharmacology23: 477-501
42.
Holsboer F., Barden N. (1996) Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev17: 187-205
43.
Humble M. (2000) Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy. Acta Psychiatr Scand Suppl402: 28-36
44.
Jensen A.G., Hansen S.H., Nielsen E.O. (2001) Adhyperforin as contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity. Life Sci68: 1593-1605
45.
Juruena M.F., Cleare A.J., Pariante C.M. (2004) The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression. Rev Bras Psiquiatr26: 189-201
46.
Karssen A.M., Meijer O.C., van der Sandt I C J, Lucassen P.J., de Lange E.C., de Boer A.G., de Kloet E.R. (2001) Multidrug resistance P-glycoprotein hampers the access of cortisol but not corticosterone to mousse and human brain. Endocrinology142: 2686-2694
47.
Karssen A.M., Meijer O.C., van der Sandt I., de Boer A.G., de Lange E.C., de Kloet E.R. (2002) The role of the efflux transporter P-glycoprotein in the brain penetration of prednisolone. J Endocrinol175: 251-260
48.
Laakmann G., Wittmann M., Gugath M., Mueller O.A., Treusch J., Wahlster U., Stalla G.K. (1984) Effects of psychotropic drugs (desimipramine, chlorimipramine, sulpiride and diazepam) on the human HPA axis. Psychopharmacology84: 66-70
49.
Laakmann G., Hinz A., Voderholzer U., Daffner C., Muller O.A., Neuhauser H., Neulinger E., Wittmann M. (1990) The influence of psychotropic drugs and releasing hormones on anterior pituitary hormone secretion in healthy subjects and depressed patients. Pharmacopsychiatry23: 18-26
50.
Lai M., McCormick J.A., Chapman K.E., Kelly P A T, Seckl J.R., Yau J L W (2003) Differential regulation of corticosteroid receptors by monoamine neurotransmitters and antidepressant drugs in primary hippocampal culture. Neuroscience118: 975-984
51.
Le Cudennec C., Naudin B., Do Rego J.C., Costentin J. (2002) Nociceptin/orphanin FQ and related peptides reduce the increase in plasma corticosterone elicited in mice by an intracerebroventricular injection. Life Sci72: 163-171
52.
Linde K., Ramirez G., Mulrow C.D., Pauls A., Weidenhammer W., Melchardt D. (1996) St. John's Wort for depression - An overview and meta-analysis of randomized clinical trials. Br Med J313: 253-258
53.
Lopez J.F., Chalmers D.T., Little K.Y., Wy S.J. (1998) Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurology of depression. Biol Psychiat43: 547-573
54.
Maisenbacher P., Kovar K.A. (1992) Adhyperforin: a homologue of hyperforin from Hypericum perforatum. Planta Med58: 291-293
55.
Marek P., Mogil J.S., Belknap J.K., Sadowski B., Liebeskind J.C. (1993) Levorphanol and swim stress-induced analgesia in selectively bred mice: evidence for genetic commonalities. Brain Res608: 353-357
56.
Martin P., Massol J., Colin J.N. (1990) Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry23: 187-194
57.
Meijer O.C., de Lange E.C., Breimer D.D., de Boer A.G., Workel J.O., de Kloet E.R. (1998) Penetration of dexamethasone into brain glucocorticoid targets is enhance in mdr1A P-glycoprotein knockout mice. Endocrinology139: 1789-1793
58.
Mogil J.S., Sternberg W.F., Balian H., Liebeskind J.C., Sadowski B. (1996) Opioid and non opioid swim stress-induced analgesia: a parametric analysis in mice. Physiol Behav59: 123-132
59.
Moreau J.L., Jenck F., Martin J.R., Mortas P., Haefely W.E. (1992) Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats. Eur Neuropsychoparmacol2: 43-49
60.
Moreau J-L., Borgulya J., Jenck F., Martin J.R. (1994) Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol5: 344-350
61.
Müller M.B., Keck M.E., Binder E.B., Kresse A.E., Hagemeyer T.P., Landgraf R., Holboer F., Uhr M. (2003) ABCB1 (MDR1)-type P-glycoproteins at the blood brain barrier modulate the activity of the hypothalamus-pituitary-adrenocortical system: implications for affective disorder. Neuropsychopharmacolgy28: 1991-1999
62.
Müller W.E., Singer A., Wonemann M., Hafner U., Rolli M., Schafer C. (1998) Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiatry31: 16-21
63.
Müller W.E., Singer A., Wonemann M. (2001) Hyperforin - Antidepressant activity by a novel mechanism of action. Pharmacopsychiatry34: 98-102.
64.
Müller W.E. (2003) St John's wort research from mode of action to clinical efficacy. Pharmacol Res47: 101-109
65.
Nemeroff C.B. (1996) The corticotropin-releasing factor (CRF) hypothesis of depression: New findings and new directions. Mol Psychiatr1: 336-342
66.
Nielsen J.A., Shannon N.J., Bero L., Moore K.E. (1986) Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons. Pharmacol Biochem Behav24: 795-799
67.
Nör C., Albring D., Ferraz A B F, Schripsema J., Pires V., Sonnet P., Guillaume D., von Poser G.L. (2004) Phloroglucinol derivatives from four Hypericum species belonging to the Trigynobrathys section. Biochem Syst Ecol32: 517-519
68.
Pariante C.M. (2003) Depression, stress and the adrenal axis. J Neuroendocrinol15: 811-812
69.
Pariante C.M. (2006) The glucocorticoid receptor: part of the solution or part of the problem?J Psychopharmacol20: 79-84
70.
Pariante C.M., Miller A.H. (2001) Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiat49: 391-404
71.
Pariante C.M., Makoff A., Lovestone S., Feroli S., Heyden A., Miller A.H., Kerwin R.W. (2001) Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol134: 1335-1343
72.
Pariante C.M., Thomas S.A., Lovestone S., Makoff A., Kerwin R.W. (2004) Do antidepressants regulate how cortisol affects the brain?Psychoneuroendocrinology29: 423-447
73.
Perloff M.D., von Moltke L.L., Stormer E., Shader R.I., Greenblatt D.J. (2001) Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol134: 1601-1608
74.
Petit-Demouliere B., Chenu F., Bourin M. (2005) Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology177: 245-255
75.
Petty F., Kramer G.L., Wu J., Davis L.L. (1997) Posttraumatic stress and depression. A neurochemical anatomy of the learned helplessness animal model. Ann N Y Acad Sci821: 529-532
76.
Porsolt R.D., Bertin A., Jalfre M. (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther229: 327-336
77.
Porsolt R.D., Anton G., Blavet N., Jalfre M. (1978a) Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol47: 379-391
78.
Porsolt R.D., Bertin A., Jalfre M. (1978b) Behavioural despair in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol51: 291-294
79.
Raap D.K., Van de Kar L.D. (1999) Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci65: 1217-1235
80.
Reul J.M., Holsboer F. (2002) Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol2: 23-33
81.
Richelson E., Pfenning M. (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol104: 277-286
82.
Robson N. K B (1990) Studies in the genus Hypericum L. (Guttiferae) 8. Sections 29. Brathys (part 2) and 30. Trigynobrathys. Bull Br Mus Nat Hist20: 1-151
83.
Rocha L., Marston A., Kaplan M A C, Stoeckli-Evans H., Thull U., Testa B., Hostettmann K. (1994) An antifungal gamma-pyrone and xanthones with monoamino oxidase inhibitory activity from Hypericum brasiliense. Phytochemistry6: 1381-1385
84.
Roz N., Mazur Y., Hirshfeld A., Rehavi M. (2002) Inhibition of vesicular uptake of monoamines by hyperforin. Life Sci71: 2227-2237
85.
Sachar E.J. (1976) Neuroendocrine dysfunction in depressive illness . Annu Rev Med27: 389-396
86.
Sachar E.J., Roffwarg H.P., Gruen P.H., Altman N., Sassin J. (1976) Neuroendocrine studies of depressive illness. Pharmakopsychiat Neuropsychopharmakol9: 11-17
87.
Sapolsky R.M. (2000) The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiat48: 755-765
88.
Schloss P., Williams D.C. (1998) The serotonin transporter: a primary target for antidepressant drugs. Psychopharmacology12: 115-121
89.
Schrader E. (2000) Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomised, controlled study in mild-moderate depression . Int Clin Psychopharmacol5: 61-68
90.
Schule C., Baghai T., Sauer N., Laakmann G. (2004a) Endocrinological effects of high-dose Hypericum perforatum extract WS 5570 in healthy subjects. Neuropsychobiology49: 58-63
91.
Schule C., Baghai T., Schmidbauer S., Bidlingmaier M., Strasburger C.J., Laakmann G. (2004b) Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology29: 185-200
92.
Seifritz E., Baumann P., Müller M.J., Annen O., Amey M., Hemmeter U., Hatzinger M., Chardon F., Holsboer-Trachsler E. (1996) Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology14: 253-263
93.
Semba J., Takahashi R. (1988) Effect of monoamine precursors on the forced-swimming test in mice. Psychopharmacology95: 222-225
94.
Stahl S.M., Pradko J.F., Haight B.R., Modell J.G., Rockett C.B., Learned-Coughlim S. (2004) A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. J Clin Psychiat6: 159-166
95.
Sunal R., Gümüsel B., Kayaalp S.O. (1994) Effect of changes in swimming area on results of behavioral despair test. Pharmacol Biochem Behav49: 891-896
96.
Tafet G.E., Bernardini R. (2003) Psychoneuroendocrinological links between chronic stress and depression. Prog Neuropsychopharmacol Biol Psychiat27: 893-903
97.
Tatsumi M., Groshan K., Blakely R.D., Richelson E. (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol340: 249-258
98.
Uhr M., Holsboer F., Muller M.B. (2002) Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice defiencient for both mdr1a and mdr1b P-glycoproteins. J Neuroencrinol14: 753-759
99.
van Praag H M. (2004) Can stress cause depression?Prog Neuropsychopharmacol Biol Psychiat28: 891-907
100.
Viana A., do Rego J.C., von Poser G., Ferraz A., Heckler A.P., Costentin J., Kuze-Rates S.M. (2005) The antidepressant-like effect of Hypericum caprifoliatum Cham & Schlecht (Guttiferae) on forced swimming test results from an inhibition of neuronal monoamine uptake. Neuropharmacology49: 1042-1052
101.
von Bardeleben U., Steiger A., Gerken A., Holsboer F. (1989) Effects of fluoxetine upon pharmacoendocrine and sleep-EEG parameters in normal controls. Int Clin Psychopharmacol4: 1-5
102.
Weber C.C., Kressmann S., Fricker G., Müller W.E. (2004) Modulation of P-glycoprotein function by St John's wort extract and its major constituents. Pharmacopsychiatry37: 292-298
103.
Weber C.C., Eckert G.P., Müller W.E. (2006) Effects of antidepressants on the brain/plasma distribution of corticosterone. Neuropsychopharmacology31: 2443-2448
104.
Webster M.J., Knable M. B, O'Grady J., Orthmann J., Weickert C.S. (2002) Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatr7: 985-994
105.
Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. (1987) Reduction of sucrose preference by chronic mild stress and its resaturation by a tricyclic antidepressant. Psychopharmacology93: 358-364
106.
Willner P., Muscat R., Papp M. ( 1992) Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci Biobehav Rev16: 525-534
107.
Willner P. (1997) Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology134: 319-329
108.
Willner P. (2005) Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology52: 90-110
109.
Yau J L W, Noble J., Seckl J.R. (1997) Site-specific regulation of corticosteroid and serotonin receptor subtype gene expression in the rat hippocampus following 3,4-methylenedioxymethamphetamine: role of corticosterone and serotonin. Neuroscience78: 111-121
110.
Yau J L W, Noble J., Thomas S., Kerwin R., Morgan P.E., Lightman S., Seckl J.R., Pariante C.M. (2007) The antidepressant desipramine requires the ABCB1 (Mdr1)-type p-glycoprotein to upregulate the glucocorticoid receptor in mice . Neuropsychopharmacology (Advance online publication; doi: 10.1038/sj.npp.1301389)
111.
Zarrindast M.R., Hosseini-Nia T. (1988) Anorectic and behavioural effects of bupropion . Gen Pharmacol19: 201-204
